Until a vaccine is available, there is an immediate need for medicines that can prevent life-threatening complications of COVID-19.
Using our AI tools and biomedical knowledge graph we identified baricitinib as a potential treatment to inhibit viral infection.
Our research was published in The Lancet and we signed the Wellcome Trust pledge to share our research in response to the emerging global health crisis
Read more →
We published a second paper which indicated that baricitinib reduces endocytosis and the body’s hyperinflammatory response to the virus, thus potentially reducing patient mortality.
Read more →
Eli Lilly (who owns baricitinib) announces that baricitinib will enter a randomised-control trial with the US National Institute of Allergy and Infectious Diseases (NIAID).
Read more →
Eli Lilly announced that they will commence an additional phase 3 clinical trial to evaluate the efficacy and safety of baricitinib to treat COVID-19.
Further experimental data supporting our AI-derived hypothesis and early results from clinical testing were published in the European Molecular Biology Organization Molecular Medicine Journal. This research was conducted in partnership with Eli Lilly.
Read more →
Positive data released from the NIAID’s randomised-control trial showed that baricitinib in combination with remdesivir reduces the recovery time in hospitalised patients with COVID-19, validating our AI-derived hypothesis.
Read more →
The FDA granted Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients, nine months after BenevolentAI's initial hypothesis was published. This decision was based on data from the NIAID ACTT-2 trial, validating our AI-derived hypothesis.
Read more →
